Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial
Pediatrics 2011;127(4):680-686
Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, Oepkes D, Brand A, Lopriore E
co-author, author 4 of 9·doi·pubmed
Summary
International guidelines recommended intravenous immunoglobulin for newborns with rhesus haemolytic disease on limited data. This double-blind, placebo-controlled trial in 80 newborns found no fewer exchange transfusions and no better neonatal outcomes.
Summary based on the published abstract.
- Type
- Randomised controlled trial
- Role
- Co-author, author 4 of 9
- Subjects
- haemolytic disease of the fetus and newborn
- PMID
- 21422084
citeSmits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, Oepkes D, Brand A, Lopriore E. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics. 2011;127(4):680-686. doi:10.1542/peds.2010-3242